Chronic Lymphocytic Leukemia

The addition of ublituximab to ibrutinib significantly improved objective response rates compared with ibrutinib alone for patients with previously treated high-risk chronic lymphocytic leukemia.

Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses PI3 kinase inhibitors in patients with chronic lymphocytic leukemia (CLL).

Jennifer Brown, MD, PhD, discusses novel agents and the future treatment landscape of chronic lymphocytic leukemia.

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses some novel approaches being used in the field of chronic lymphocytic leukemia.

Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the novel agent acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL).

Researchers hope the acquired ibrutinib resistance mutations BTK and PLCG2 can be used as biomarkers for early intervention opportunities in patients with chronic lymphocytic leukemia.

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses PD-1 expression in patients with chronic lymphocytic leukemia (CLL) who were treated with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica).

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).

Jeffrey Jones, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses a concern of venetoclax (Venclexta) in a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia (CLL).

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses a clinical trial exploring the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).

Jennifer A. Woyach, MD, an associate professor of Medicine in the Division of Internal Medicine at The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of the CD19-directed antibody MOR208 in combination with lenalidomide (Revlimid) or ibrutinib (Imbruvica) in patients with CLL.

Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.

A study presented at the 2016 ASH Annual Meeting identified potential biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia.

Jennifer Woyach, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the preliminary efficacy results of the MOR208 trial in chronic lymphocytic leukemia (CLL).

At 29 months’ follow-up, frontline ibrutinib reduced the risk of of progression or death by 88% versus chlorambucil in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to the latest findings from the phase III RESONATE-2 trial.

Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses BTK inhibition in chronic lymphocytic leukemia (CLL).

Jennifer A. Woyach, MD, discusses the preliminary results of an ongoing phase II trial of MOR208 combination regimens in chronic lymphocytic leukemia.

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses combination regimens that seem promising and are under investigation in the treatment landscape of chronic lymphocytic leukemia.

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses BGB-3111, a new BTK inhibitor being used in the treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Jennifer Woyach, MD, associate professor, The Ohio State University, discusses ibrutinib resistance in patients with chronic lymphocytic leukemia.

Veronique Leblond, MD, of Pietra - Hospital, Paris, France, discusses the current treatment landscape of chronic lymphocytic leukemia (CLL).

It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.

Danelle James, MD, MAS, head of Oncology at Pharmacyclics, assistant adjunct professor in the Division of Hematology-Oncology at the Chronic Lymphocytic Leukemia Research Consortium, discusses the RESONATE-2 study of ibrutinib (Imbruvica) versus chlorambucil through 5 years of treatment.

Danelle James, MD, discusses the updated RESONATE-2 data presented at the ASH Annual Meeting and the next steps with ibrutinib in CLL.